Agenus (AGEN) AI Stock Analysis

• Market Cap: $142.46M
• Dividend Yield: N/A
• Average Volume (3M): 482.32K
• Price to Earnings (P/E): 811.9
• Beta (1Y): 3.20
• Revenue Growth: -33.41%
• EPS Growth: 81.19%
• Country: US
• Employees: 316
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.44
• Shares Outstanding: 38,398,354
• 10 Day Avg. Volume: 696,233
• 30 Day Avg. Volume: 482,322
• PEG Ratio: -8.12
• Price to Book (P/B): -0.34
• Price to Sales (P/S): 0.82
• P/FCF Ratio: -0.59
• Enterprise Value/Market Cap: 3.33
• Enterprise Value/Revenue: 4.15
• Enterprise Value/Gross Profit: 11.64
• Enterprise Value/Ebitda: 6.66
• 1Y Price Target: $23.00
• Price Target Upside: 519.95% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1
• EPS Forecast (FY): 1.5
• Revenue Forecast (FY): $179.52M

• Rating: 50 Neutral
• Price Target: $4.00 ▲(7.82% Upside)
• Action: Reiterated Date: 03/18/26
• Date: Action: Reiterated 03/18/26

Overall score is held back primarily by weak financial performance (negative equity and substantial cash burn despite 2025 improvements). Technicals are moderately supportive with price above key averages and positive MACD, and the Zydus collaboration is a notable positive corporate event, but valuation signals are limited due to a non-meaningful P/E and no dividend yield.

Positive Factors

Strategic Zydus collaboration secures manufacturing and funding

The Zydus deal monetizes non-core assets, injects cash and equity, and guarantees committed U.S. manufacturing capacity for the Phase 3 BOT+BAL program. That reduces execution risk for late-stage trials, ties milestone revenue to program advancement, and strengthens the company’s operational continuity.

Material reduction in debt in 2025

A large decline in reported debt markedly lowers interest and refinancing pressure, improving financial flexibility. With lower explicit leverage, the company has more capacity to allocate cash toward clinical development and to manage near-term obligations without depending solely on dilutive equity raises.

Operational trajectory: revenue rebound and narrowed losses

Improving top-line and much smaller net losses indicate the business is moving toward stabilization. A trajectory to near-breakeven reduces future cash needs if sustained, lowering dilution risk and increasing the likelihood of funding clinical milestones from operating improvements and partner payments.

Negative Factors

Persistently negative shareholder equity

Sustained negative equity reflects accumulated losses and undermines balance sheet resilience. It limits access to non-dilutive financing, raises creditor and counterparty concerns, and can impede strategic flexibility during setbacks, leaving the company vulnerable to funding shocks over the medium term.

Large, ongoing operating cash burn

Very negative operating cash flow indicates the company consumes substantial capital to fund R&D and operations. Continued cash burn makes the firm reliant on external funding or partner milestones, increasing dilution risk and potentially delaying programs if funding gaps emerge over the next several quarters.

Increased potential equity dilution from amended warrants

A materially reduced warrant strike raises the likelihood of exercise and incremental share issuance, diluting existing holders. In the context of negative equity and ongoing cash needs, greater dilution can weaken per-share economics and complicate future capital raises and investor returns over the medium term.

Agenus Business Overview & Revenue Model

Company Description

Agenus Inc., a clinical-stage immuno-oncology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops vaccine programs comprising Prophage vaccine candidate; and QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, an anti-PD-1 antagonist that has completed Phase II clinical trial to treat second line cervical cancer; AGEN1181, an anti-CTLA-4 monospecific antibody that is in Phase 1/2 clinical trial; AGEN2373, an anti-CD137 monospecific antibody that is in Phase 1 clinical trial; AGEN1423, a tumor microenvironment conditioning anti-CD73/TGFß TRAP bi-functional antibody that has completed Phase 1 clinical trial; AGEN1777, an anti-TIGIT bispecific antibodies; and AGEN1327, a human monoclonal antibody. In addition, the company develops INCAGN1876, an anti-GITR monospecific antibody; INCAGN1949, an anti-OX40 monospecific antibody; INCAGN2390, an anti-TIM-3 monospecific antibody; INCAGN2385, an anti-LAG-3 monospecific antibody; MK-4830, a monospecific antibody targeting ILT4; AGENT 797, an iNKT cells that is in Phase 1 clinical trial for solid tumors, multiple myeloma, and viral ARDS, as well as in clinical stage to treat hematological malignancies and multiple myeloma/B cells; and AGEN1884, a first-generation anti-CTLA-4 monospecific antibody. Agenus Inc. operates under ASV, Agenus, AutoSynVax, EVAMPLIX, MiNK, PSV, PhosPhoSynVax, Prophage, Retrocyte Display, and Stimulon trademarks. It has collaborations with Incyte Corporation, Merck Sharpe & Dohme, Recepta Biopharma SA, and Gilead Sciences, Inc. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.

How the Company Makes Money

Agenus primarily generates revenue from collaboration and licensing arrangements rather than from product sales, as it is a clinical-stage company. Key revenue streams can include (1) upfront payments and option fees received when it enters strategic partnerships granting other parties rights to develop and/or commercialize specific drug candidates or technologies; (2) research and development funding or cost reimbursements from partners under collaboration agreements; (3) milestone payments that may be earned upon the achievement of specified development, regulatory, or commercial events; and (4) royalties on net sales if partnered products are successfully commercialized. In addition, like many pre-commercial biotechnology companies, it may raise capital through equity or other financings to fund operations; however, financing proceeds are not reported as revenue under U.S. GAAP.

Agenus Financial Statement Overview

Summary

Financial profile remains high-risk: persistently negative shareholder equity and large ongoing operating/free-cash-flow burn outweigh 2025 stabilization (modest revenue rebound, sharply narrowed losses, and significant debt reduction).

Income Statement

Revenue has been volatile, with a sharp contraction from 2021 to 2024 and a modest rebound in 2025 (+6.9% YoY). Profitability remains the core weakness: margins were deeply negative in 2022–2024, and while 2025 shows a near-breakeven net margin (~-2.7%), the business is still not consistently profitable. Prior profitability in 2021 (positive operating earnings) looks non-recurring given the subsequent multi-year losses.

Balance Sheet

The balance sheet is stressed by persistently negative shareholder equity (2022–2025), which reduces financial flexibility and increases risk for equity holders. Debt levels improved materially in 2025 (total debt fell to ~$10.1M from ~$94.9M in 2024), but negative equity still leaves leverage optics and capital structure quality weak. Total assets have also declined from 2021–2022 levels, suggesting reduced balance sheet capacity over time.

Cash Flow

Cash generation remains a major concern: operating cash flow is strongly negative across recent years (e.g., -$158.3M in 2024 and 2025), and free cash flow is similarly negative, indicating ongoing cash burn to fund operations. While free cash flow improved in 2025 versus the prior year (as reflected by the strong growth rate), the company is still meaningfully cash-flow negative and likely reliant on external funding to sustain operations.

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	114.20M	103.46M	156.31M	98.02M	295.67M
Gross Profit	103.17M	-52.55M	-81.37M	-99.23M	113.59M
EBITDA	-10.56M	-101.30M	-145.92M	-161.85M	43.78M
Net Income	115.00K	-227.21M	-245.76M	-220.07M	-23.93M
Balance Sheet
Total Assets	226.80M	226.27M	313.91M	413.56M	465.96M
Cash, Cash Equivalents and Short-Term Investments	3.00M	40.44M	76.11M	193.36M	306.92M
Total Debt	334.90M	94.87M	93.19M	78.43M	58.29M
Total Liabilities	333.60M	532.70M	462.30M	468.46M	418.05M
Stockholders Equity	-271.11M	-326.38M	-160.33M	-61.28M	34.44M
Cash Flow
Free Cash Flow	-158.89M	-158.89M	-234.16M	-228.44M	-23.67M
Operating Cash Flow	-158.31M	-158.31M	-224.20M	-175.37M	10.14M
Investing Cash Flow	27.00K	27.00K	3.40M	-33.61M	-43.15M
Financing Cash Flow	122.84M	122.84M	119.87M	95.83M	225.26M

Agenus Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 3.71
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AGEN, the sentiment is Positive. The current price of 3.71 is above the 20-day moving average (MA) of 3.31, above the 50-day MA of 3.29, and below the 200-day MA of 4.22, indicating a neutral trend. The MACD of 0.14 indicates Negative momentum. The RSI at 58.78 is Neutral, neither overbought nor oversold. The STOCH value of 71.48 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AGEN.

Agenus Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ONCY	52 Neutral	$102.23M	-3.43	-755.18%	―	―	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
AGEN	50 Neutral	$142.46M	811.87	-0.04%	―	-33.41%	81.19%
SPRO	48 Neutral	$133.52M	-3.58	-125.91%	―	-67.38%	-1076.54%
INO	45 Neutral	$109.17M	-9.60	-353.36%	―	-10.36%	42.36%
TIL	44 Neutral	$57.99M	-2.22	-53.02%	―	―	1.40%
HURA	41 Neutral	$117.80M	-4.42	-193.06%	―	―	99.21%

Agenus Corporate Events

Agenus Forms Major Strategic Collaboration with Zydus Lifesciences

On January 15, 2026, Agenus closed a $141 million strategic collaboration with Zydus Lifesciences that combines the $75 million sale of its Emeryville and Berkeley, California biologics manufacturing operations, a $16 million equity investment for roughly 2.1 million Agenus shares at $7.50 each, and up to $50 million in contingent milestone payments tied to future BOT+BAL production orders. The transaction, which constitutes a significant business disposition for Agenus, grants Zydus exclusive rights to develop and commercialize botensilimab and balstilimab in India and Sri Lanka in return for a 5% royalty on net sales, while securing committed long-term U.S. manufacturing capacity at the divested facilities to support Agenus’ Phase 3 BOT+BAL program, global access initiatives, and prospective commercialization, thereby strengthening its balance sheet and positioning the company to advance its late-stage immunotherapy strategy in microsatellite-stable colorectal cancer.

The most recent analyst rating on (AGEN) stock is a Buy with a $23.00 price target. To see the full list of analyst forecasts on Agenus stock, see the AGEN Stock Forecast page.

Agenus Consolidates Financial Leadership With Interim CFO Appointment

Effective January 8, 2026, Agenus Inc.’s board appointed Chairman and Chief Executive Officer Dr. Garo Armen as interim Chief Financial Officer and Principal Financial Officer, consolidating key leadership roles under a seasoned industry veteran who co-founded the company and previously led the restructuring of Elan Corporation. Armen’s compensation terms remain unchanged, with salary and potential bonuses paid in Agenus stock, and the company emphasized that his appointment involved no special arrangements, related-party relationships, or transactions. On the same date, the board named Senior Director of Financial Reporting and Compliance, Austin Charette, as Principal Accounting Officer, formalizing leadership over external reporting, technical accounting, internal controls, and new accounting standards implementation, also without any new compensation arrangements or related-party considerations, signaling a continuity-focused approach to financial governance and compliance.

The most recent analyst rating on (AGEN) stock is a Sell with a $4.50 price target. To see the full list of analyst forecasts on Agenus stock, see the AGEN Stock Forecast page.

Agenus amends Ligand agreement, modifies warrant holder rights

On January 3, 2026, Agenus Inc., together with Agenus Royalty Fund, LLC and Agenus Holdings 2024, LLC, entered into an amendment and release agreement with Ligand Pharmaceuticals that altered the terms of an existing purchase and sale agreement and warrant arrangement. Under the amendment, Ligand agreed to release liens on certain Agenus assets in exchange for a substantial reduction in the warrant exercise price from $17.30 per share to $7.50 per share, a move that may improve Agenus’s operational flexibility by freeing encumbered assets while increasing the potential equity dilution for existing shareholders if the lower-priced warrants are exercised.

The most recent analyst rating on (AGEN) stock is a Hold with a $4.50 price target. To see the full list of analyst forecasts on Agenus stock, see the AGEN Stock Forecast page.